

# Octavio Ballesta-LÃ³pez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5002531/publications.pdf>

Version: 2024-02-01

11  
papers

103  
citations

1683354

5  
h-index

1473754

9  
g-index

11  
all docs

11  
docs citations

11  
times ranked

143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1989-2007.	0.8	26
2	&lt;p&gt;IDH1-mutated relapsed or refractory AML: current challenges and future prospects&lt;/p&gt;. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 19-32.	1.2	24
3	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <i>Blood Reviews</i> , 2020, 44, 100675.	2.8	23
4	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 659-668.	0.6	10
5	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e41-e45.	0.5	9
6	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 1-18.	1.0	7
7	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 612-620.	0.7	2
8	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , 2021, 106, 724-733.	1.1	1
9	Healthcare Resource Utilization among Patients between 60â€75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 1921.	1.7	1
10	Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 268-278.	0.5	0
11	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. <i>Future Oncology</i> , 2021, 17, 215-227.	1.1	0